{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T10:02:41Z","timestamp":1788343361735,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T00:00:00Z","timestamp":1720224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Malignant pleural mesothelioma (MPM) is an aggressive cancer with long latency and poor prognosis. The real-world treatment patterns and humanistic burden of MPM in an international cohort of patients were recently published. Spanish data are currently lacking and are reported here.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods\/Patients<\/jats:title>\n                    <jats:p>Data were collected from three sources: physician-abstracted demographic, clinical and treatment characteristics of patients with MPM; patient-completed questionnaires on treatment satisfaction, symptoms, caregiver use, and impact of the disease; and caregiver-completed questionnaire reporting their activity and its impact on their daily life.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The 241 patients in Spain were primarily elderly (median age: 67 years), male, retired\/unemployed\/on long-term sick leave, and diagnosed at stage IV with unresectable disease. Exposure to asbestos was detected (54%, 101\/188). First-line treatment (1L) consisted primarily of doublet chemotherapy (86%, 207\/241). Of 102 patients who completed 1L at data abstraction, 67 were receiving maintenance therapy, most commonly singlet chemotherapy with pemetrexed. Best supportive care was given to 29 patients, primarily after 1L (86.2%, 25\/29). Symptom burden was high and health-related quality of life was poor and declined with progression: mean (SD) EQ-5D score and EQ-5D visual analogue scale score were 0.615 (0.285) and 60.8 (17.1) in 1L and 0.497 (0.370) and 56.1 (19.5) in second line. Overall, 67% of patients (162\/241) required daily assistance from their caregiver, who reported an impact on their psychological well-being.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with MPM in Spain were overall treated according to treatment guidelines at the time. Nevertheless, a considerable burden of disease was reported by patients and caregivers.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12094-024-03591-5","type":"journal-article","created":{"date-parts":[[2024,7,6]],"date-time":"2024-07-06T03:01:47Z","timestamp":1720234907000},"page":"213-222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment patterns and humanistic burden of malignant pleural mesothelioma in Spain"],"prefix":"10.1007","volume":"27","author":[{"given":"Susana","family":"Cedres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Calvete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Taylor-Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0043-8012","authenticated-orcid":false,"given":"N\u00e9stor \u00c1lvarez","family":"Ayerza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Vilanova","family":"Larena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Daumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,6]]},"reference":[{"key":"3591_CR1","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.path.2019.10.001","volume":"13","author":"DR Fels Elliott","year":"2020","unstructured":"Fels Elliott DR, Jones KD. Diagnosis of mesothelioma. Surg Pathol Clin. 2020;13:73\u201389.","journal-title":"Surg Pathol Clin"},{"key":"3591_CR2","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMra1912719","volume":"385","author":"SM Janes","year":"2021","unstructured":"Janes SM, Alrifai D, Fennell DA. Perspectives on the treatment of malignant pleural mesothelioma. N Engl J Med. 2021;385:1207\u201318.","journal-title":"N Engl J Med"},{"key":"3591_CR3","doi-asserted-by":"publisher","first-page":"1631","DOI":"10.1097\/JTO.0b013e31826915f1","volume":"7","author":"VW Rusch","year":"2012","unstructured":"Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, et al. Initial analysis of the international association for the study of lung cancer mesothelioma database. J Thorac Oncol. 2012;7:1631\u20139.","journal-title":"J Thorac Oncol"},{"key":"3591_CR4","unstructured":"National Cancer Institute. SEER*Explorer: An interactive website for SEER cancer statistics. 2023. https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html. Accessed 8 Oct 2023."},{"key":"3591_CR5","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.jtho.2023.01.095","volume":"18","author":"J Huang","year":"2023","unstructured":"Huang J, Chan SC, Pang WS, Chow SH, Lok V, Zhang L, et al. Global incidence, risk factors, and temporal trends of mesothelioma: a population-based study. J Thorac Oncol. 2023;18:792\u2013802.","journal-title":"J Thorac Oncol"},{"key":"3591_CR6","unstructured":"Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Pi\u00f1eros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer. In: Global Cancer Observatory. 2020. https:\/\/gco.iarc.fr\/today. Accessed 8 Oct 2023."},{"key":"3591_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jss.2015.01.043","volume":"196","author":"RR Meyerhoff","year":"2015","unstructured":"Meyerhoff RR, Yang CFJ, Speicher PJ, Gulack BC, Hartwig MG, D\u2019Amico TA, et al. Impact of mesothelioma histologic subtype on outcomes in the surveillance, epidemiology, and end results database. J Surg Res. 2015;196:23\u201332.","journal-title":"J Surg Res"},{"key":"3591_CR8","doi-asserted-by":"publisher","first-page":"21357","DOI":"10.1038\/s41598-021-00831-4","volume":"11","author":"S Cedres","year":"2021","unstructured":"Cedres S, Assaf JD, Iranzo P, Callejo A, Pardo N, Navarro A, et al. Efficacy of chemotherapy for malignant pleural mesothelioma according to histology in a real-world cohort. Sci Rep. 2021;11:21357.","journal-title":"Sci Rep"},{"key":"3591_CR9","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003;21:2636\u201344.","journal-title":"J Clin Oncol"},{"key":"3591_CR10","doi-asserted-by":"publisher","first-page":"6881","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Van Meerbeeck","year":"2005","unstructured":"Van Meerbeeck JP, Gaafar R, Manegold C, Van Klaveren RJ, Van Marck EA, Vincent M, et al. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the National Cancer Institute. J Clin Oncol. 2005;23:6881\u20139.","journal-title":"J Clin Oncol"},{"key":"3591_CR11","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","volume":"397","author":"P Baas","year":"2021","unstructured":"Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021;397:375\u201386.","journal-title":"Lancet"},{"key":"3591_CR12","unstructured":"OPDIVO\u00ae (nivolumab) [package insert]. Princeton NJ:Bristol-Myers Squibb Company; 2023."},{"key":"3591_CR13","unstructured":"OPDIVO\u00ae (nivolumab). European Medicines Agency SmPC. Dublin, Ireland:Bristol-Myers Squibb Pharma EEIG; 2023."},{"key":"3591_CR14","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1016\/S0140-6736(23)01613-6","volume":"402","author":"Q Chu","year":"2023","unstructured":"Chu Q, Perrone F, Greillier L, Tu W, Piccirillo MC, Grosso F, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023;402:2295\u2013306.","journal-title":"Lancet"},{"key":"3591_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.annonc.2021.11.005","volume":"33","author":"S Popat","year":"2022","unstructured":"Popat S, Baas P, Faivre-Finn C, Girard N, Nicholson AG, Nowak AK, et al. Malignant pleural mesothelioma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2606. Ann Oncol. 2022;33:129\u201342.","journal-title":"Ann Oncol"},{"key":"3591_CR16","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1080\/03007995.2016.1226165","volume":"32","author":"S Mercadante","year":"2016","unstructured":"Mercadante S, Degiovanni D, Casuccio A. Symptom burden in mesothelioma patients admitted to home palliative care. Curr Med Res Opin. 2016;32:1985\u20138.","journal-title":"Curr Med Res Opin"},{"key":"3591_CR17","first-page":"1193","volume":"9","author":"A Granieri","year":"2013","unstructured":"Granieri A, Tamburello S, Tamburello A, Casale S, Cont C, Guglielmucci F, et al. Quality of life and personality traits in patients with malignant pleural mesothelioma and their first-degree caregivers. Neuropsychiatr Dis Treat. 2013;9:1193\u2013202.","journal-title":"Neuropsychiatr Dis Treat"},{"key":"3591_CR18","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.3390\/ijerph20021570","volume":"20","author":"MD Guerra-Mart\u00edn","year":"2023","unstructured":"Guerra-Mart\u00edn MD, Casado-Espinosa MDR, Gavira-L\u00f3pez Y, Holgado-Castro C, L\u00f3pez-Latorre I, Borrallo-Riego \u00c1. Quality of life in caregivers of cancer patients: a literature review. Int J Environ Res Public Health. 2023;20:1570.","journal-title":"Int J Environ Res Public Health"},{"key":"3591_CR19","doi-asserted-by":"publisher","first-page":"2587","DOI":"10.1007\/s11136-023-03410-4","volume":"32","author":"A Moore","year":"2023","unstructured":"Moore A, Bennett B, Taylor-Stokes G, Daumont MJ. Caregivers of patients with malignant pleural mesothelioma: who provides care, what care do they provide and what burden do they experience? Qual Life Res. 2023;32:2587\u201399.","journal-title":"Qual Life Res"},{"key":"3591_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-022-09750-7","volume":"22","author":"A Moore","year":"2022","unstructured":"Moore A, Bennett B, Taylor-Stokes G, McDonald L, Daumont MJ. Malignant pleural mesothelioma: treatment patterns and humanistic burden of disease in Europe. BMC Cancer. 2022;22:693.","journal-title":"BMC Cancer"},{"key":"3591_CR21","doi-asserted-by":"crossref","unstructured":"Szende A, Janssen B, Cabas\u00e9s J. Self-reported population health: an international perspective based on EQ-5D. Springer Open. 2014.","DOI":"10.1007\/978-94-007-7596-1"},{"key":"3591_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.lungcan.2020.06.034","volume":"147","author":"J Remon","year":"2020","unstructured":"Remon J, Nadal E, D\u00f3mine M, Ruffinelli J, Garc\u00eda Y, Pardo JC, et al. Malignant pleural mesothelioma: treatment patterns and outcomes from the Spanish Lung Cancer Group. Lung Cancer. 2020;147:83\u201390.","journal-title":"Lung Cancer"},{"key":"3591_CR23","doi-asserted-by":"publisher","first-page":"LBA8505","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA8505","volume":"41","author":"QS Chu","year":"2023","unstructured":"Chu QS, Piccirillo MC, Greillier L, Grosso F, Lo Russo G, Florescu M, et al. IND227 phase III (P3) study of cisplatin\/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleural mesothelioma (PM): a CCTG, NCIN, and IFCT trial. J Clin Oncol. 2023;41:LBA8505.","journal-title":"J Clin Oncol"},{"key":"3591_CR24","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/S1470-2045(21)00471-X","volume":"22","author":"DA Fennell","year":"2021","unstructured":"Fennell DA, Ewings S, Ottensmeier C, Califano R, Hanna GG, Hill K, et al. Nivolumab versus placebo in patients with relapsed malignant mesothelioma (CONFIRM): a multicentre, double-blind, randomised, phase 3 trial. Lancet Oncol. 2021;22:1530\u201340.","journal-title":"Lancet Oncol"},{"key":"3591_CR25","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/S0140-6736(15)01238-6","volume":"387","author":"G Zalcman","year":"2016","unstructured":"Zalcman G, Mazieres J, Margery J, Greillier L, Audigier-Valette C, Moro-Sibilot D, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016;387:1405\u201314.","journal-title":"Lancet"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03591-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-024-03591-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-024-03591-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T01:27:01Z","timestamp":1736904421000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-024-03591-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3591"],"URL":"https:\/\/doi.org\/10.1007\/s12094-024-03591-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,6]]},"assertion":[{"value":"16 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"S.C. reports an advisory role and\/or travel compensation: F. Hoffmann La Roche AG, Pfizer, Boehringer Ingelheim, MSD Oncology, Bristol Myers Squibb recipient, and Amphera. J.C. reports an advisory role and\/or travel compensation: Pfizer, Bristol Myers Squibb, and F. Hoffmann La Roche AG. G.T.S. Adelphi Real World employee. N.A.A. BMS employee. D.V.L. BMS employee. M.D. BMS employee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interests"}},{"value":"This study was approved by the Western Institutional Review Board (IRB Number: 20183141). The study was performed in accordance with the relevant guidelines and regulations, including the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was provided by patients and caregivers when providing their data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}